Decreased Antimicrobial Resistance Gene Richness Following Fecal Microbiota, Live-jslm (REBYOTA®) Administration: Post Hoc Analysis of PUNCH CD3 - Takeaways - MDSpire

Decreased Antimicrobial Resistance Gene Richness Following Fecal Microbiota, Live-jslm (REBYOTA®) Administration: Post Hoc Analysis of PUNCH CD3

  • By

  • Elizabeth Adamowicz

  • Colleen S Kraft

  • Tonya Ward

  • Nirja Mehta

  • William D Shannon

  • Rohan Mishra

  • Ken F Blount

  • July 2, 2025

  • 0 min

Share

  • 1

    Fecal microbiota, live-jslm (REBYOTA) administration reduces antimicrobial resistance gene richness in patients after recurrent Clostridioides difficile infection.

  • 2

    Participants receiving REBYOTA showed lower antibiotic resistance gene richness compared to placebo responders, evident as early as one week post-administration.

  • 3

    REBYOTA administration led to decreased richness of high-risk antibiotic resistance genes associated with public health threats.

  • 4

    The study supports microbiota-based products as a potential strategy to mitigate the risk of infections from antimicrobial-resistant organisms.

  • 5

    The PUNCH CD3 study demonstrated REBYOTA's efficacy in preventing recurrent CDI with a treatment success rate of 70.6%.

Original Source(s)

Decreased Antimicrobial Resistance Gene Richness Following Fecal Microbiota, Live-jslm (REBYOTA®) Administration: Post Hoc Analysis of PUNCH CD3

  • by Elizabeth Adamowicz, Colleen S Kraft, Tonya Ward, Nirja Mehta, William D Shannon, Rohan Mishra, Ken F Blount

  • July 2, 2025

Related Content

Remodeling mechanisms and intervention strategies of the oral mucosal immune barrier

Insights from Multi-Omics on Maternal-Fetal Immune Tolerance in Recurrent Pregnancy Loss: Mechanisms, Integration Challenges, and Clinical Implications

Sex Disparities May Persist in CF Despite Modulators

Review findings suggested female patients with cystic fibrosis may continue to experience worse pulmonary outcomes despite highly effective modulator therapy